NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug
Thursday, April 20, 2017 - 09:42
in Health & Medicine
Findings from a clinical trial led by a researcher at NYU Langone's Perlmutter Cancer Center helped pave the way for the recent, accelerated approval by the U.S. Food and Drug Administration (FDA) of a highly effective immunotherapy as first line treatment for patients with advanced bladder cancer who are not eligible for treatment with standard chemotherapy